height velocity and partial GH deficiency in response to two pharmacological tests (maximum peak 11 ng/ml) received GRF for 6 months (10 mcg/kg/day) as a subcutaneous injection (8 p.m.). 24-hours GH secretion was studied before and after 3 months of treatment : SmC dosage and a IV CRF test (2 mcg/kg) was done before and after 6 months of treatment. Lower leg length was studied every 3 weeks by knemometry and statural growth at 3 months intervals.
Height velocity increased in 5 cases from 2.5 + 0.5 to 4.4 2 1.1 cm for the 6 months period and showed no change in 2 cases. Knemometric growth rate is subject to wide variations and is dlfficult to take into account. There was no sign of desensitizat~on: 24-hour secretion (mx peak and I.C.) was hlgher after 3 months treatment (m = 16.2 2 7.5 ng/ml and 3.7 2 1.2 ng/ml/min before, 29 + 17.9 ng/ml and 4.5 + 2.9 ng/ml/mln afterwerds), as was the GH peak in the IV GRF test after 6 months treatment (m = 36.1 ng/ml before, 47.8 ng/ml afterwards). SmC level was hlgher on average after 6 months treatment (1.9 + 1 U / m l and 0.8 + 0.5 U/ml before treatment). The analysis of the various parameters (GH secretion, SmC) provided no elements to account for the lack of therapeutic response in the 2 cases. These results suggest that GRF treatment may be considered as a therapeutic alternative in GH deflcienc~es. ns bicchenical and p m t h rest o W ( 1 -2 9 ) W therapy were studied in 18 prepbertal W-deficient children (14 idiopathic, 3 cranial irradiation, 1 septooptic dysplasia; 16 vale, 2 fenale, mean age 9.5 years, range 6.8 -14.2 years). 81 deficiency was defined as a peak 81 to stiniulation of less tM 7 nWl. Farteen children bad rwzived t r e a m t which was stopped at least 3 m n t k before the trial. CWJ1 was given as M c e daily sc injectiwls in indiviw doses of 250 pg (children less ttm 20 ly bw), and 500 p g (p?ater ttm 20 kg). Peak senm 81 respnse t o BIRH before treatment was 23.8 + 6.3 mU/1 (mean + SE) and after 3 m n t k 27.4 + 4.2 nU/1; indicat-no desensitisatior~ effect. Thirteen of the 18 skwed an i n c m n t in h e w t velocity after 3 rmnths Wrapy, in 6 this was p t e r t b n 2 an/year and in 3 greater ttm 5 an/year.
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lhw childrefi s h m d a p t e r kigbt velccity on CWkl than on M. Ei&t children have mpleted 6 m n t k therapy and 3 have shmn an i n c m n t in height velocity of 0.4, 2.5, and 3.1 adyear. ?here was no correlation be-n W p x t h rzspnse at 3 m t k and pre-tmtnent 81 respnse t o BIRH. In conclusion, v e have s h U=t Me daily sc (MRH therapy is a safe treatxent which p m t e d linear fgmtk at 3 m n t k in 13 of 1 8 81-deficient children. Hcwever, p r d i~t o~~ Of gad p m t h r e s p r s s could not be identified. 5 children (8.24+/-3.63 years) with growth retardation (3.4 +/-0.9 DS)bone age retardation (3.13+/-2.40 years) and insufficient growth velocity (3.9+/-0.6 cmlyear) related with complete (n=2) or partial (n=3) GH deficiency were treated with a daily dose of 300 mcg GRF administred subcutaneously (SC)every other week for a 6 months period. GH response to SC GRF administration, GH and GRF antibodies and somatomedins were studied on repeated blood samples performed on day I and day 8 of the first week of treatment as well as at the end of the 6 months therapy. Growth velocity increased to 6.16+/-1.17 cm/year. 3 of the 5 patients have accelerated growth mainly for the first 3 months. Linear growth was increased in complete (+2.5 and 4.3 cmlyear) more than in partial (+0.4, +0.8 and +3.3 cmfyear) GH deficient children. The area under the GH curve after GRF administration was 1050.7+/-767.7 on day 1, 472.1+/-103.2 on day 8 and 631.9 91-148.1 ng/ml x min. after 6 months therapy. No major change in other hormonal evaluations was noted. These results confirm that GRF can stimulate linear growth in some GH deficient children and lead to discuss the role of limiting factors in its long term effects such as desensitization, antibodies or somatostatin.
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PULSATILE GROWTH HORMONE RELEASING HORMONE TREATMENT OF CH DEFICIENCY
We have treated 1 1 prepubertal children (7M;4F) with idiopathic GH deficiency due to pituitary hypoplasia using GHRH 1-40. This was administered subcutaneously for 4 pulses at 3 hourly intervals at night in a dose of 1-2pg/kg/pulse. Blood samples for CH concentrations were taken at 20 minute intervals for 24 hours before treatment and throughout the study monthly at night.
Pulsatile GH secretion was induced in 10 children from the first night of treatment and the response augmented with time. Growth velocity in 8 of 1 1 children increased from 3.3cm/yr (range 1.7 to 4.9) before treatment to 6.9cmIyr (range 5-8.5) on GHRH. 2 children had no change in height velocity and one had a progressive diminution of CH secretion and a fall in growth velocity.
GHRH (Ivg/kg) was also administered intravenously to all children before treatment and at 3 monthly intervals. Although a GH response was seen on all occasions, the responses predicted neither the GH concentrations nor the growth velocities obtained on long term s.c. treatment.
Pulsatile administration of GHRH 1-40 was effective in inducing GH secretion and promoting growth acceleration in the majority of children with idiopathic GH deficiency. Res. 18, 107 (1984) 
